Related Experiment Video
Updated: Jun 20, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Prognostic value of microvessel density in prostate cancer: a tissue microarray study.
Andreas Erbersdobler1, Hendrik Isbarn, Kira Dix
1Institute of Pathology, Charité University Hospital Berlin, Charitéplatz 1, 10117, Berlin, Germany. andreas.erbersdobler@charite.de
World Journal of Urology
|August 29, 2009
Summary
Intratumoral microvessel density (MVD) correlates with prostate cancer aggressiveness but is not an independent prognostic factor for PSA recurrence after surgery. Routine reporting of MVD is not recommended.
Area of Science:
- Oncology
- Pathology
- Urology
Background:
- Angiogenesis, indicated by microvessel density (MVD), is crucial in tumor progression.
- MVD's prognostic value in prostate cancer, particularly from small biopsies, remains uncertain.
- This study investigates MVD's role in a large prostate cancer cohort.
Purpose of the Study:
- To evaluate the prognostic potential of intratumoral microvessel density (MVD) in prostate cancer.
- To assess the correlation of MVD with pathological parameters in prostatectomy specimens.
- To determine if MVD predicts biochemical recurrence after radical prostatectomy.
Main Methods:
- A tissue microarray of 3,261 prostatectomy specimens was analyzed.
- Microvessel density (MVD) was quantified using CD31 immunohistochemistry.
- MVD was correlated with clinicopathological data and patient follow-up.
Main Results:
- MVD was significantly higher in cancerous tissue than benign tissue (P < 0.001).
- MVD correlated with pathological T-classification, Gleason score, and peripheral zone location (P < 0.001).
- High MVD (≥36) predicted PSA recurrence in univariable analysis (P = 0.03) but not in multivariable analysis.
Conclusions:
- Intratumoral microvessel density (MVD) is linked to prostate cancer aggressiveness.
- MVD did not emerge as an independent prognostic factor for recurrence.
- Routine pathological reporting of MVD in prostate cancer is not currently advised.
